Inhibrx Biosciences Inc. (INBX) Stock Ticker
INBX right now
Market factors today
Unlock the full INBX picture
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
INBX stock facts
| Ticker symbol | INBX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.5B |
| CEO | Mark Lappe |
| Employees | 110 |
| Headquarters | La Jolla, CA, US |
| IPO date | 2024-05-29 |
| Website | www.inhibrx.com |
What you can see for INBX on Tickr
Live INBX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the INBX report.
Rankings
FAQ
What is the ticker symbol for Inhibrx Biosciences Inc.?
The ticker symbol for Inhibrx Biosciences Inc. is INBX, listed on the NASDAQ.
What is INBX?
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way…